Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additional dose of 10-valent pneumococcal conjugate vaccine or Prevenar at 4 years of age
2008-007605-37Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 10-valent pneumococcal conjugate vaccine, pneumococcal 7-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Immune response after additional dose of 10-valent pneumococcal conjugate vaccine at approximately 4 years of age. Started Mar 2009; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 7-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2008-007605-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007605-37.